#begin document (wsj_1934.en); part 000
wsj_1934.en	0	0	A	(3
wsj_1934.en	0	1	new	-
wsj_1934.en	0	2	drug	3)
wsj_1934.en	0	3	to	-
wsj_1934.en	0	4	prevent	-
wsj_1934.en	0	5	the	-
wsj_1934.en	0	6	rejection	-
wsj_1934.en	0	7	of	-
wsj_1934.en	0	8	transplanted	-
wsj_1934.en	0	9	organs	-
wsj_1934.en	0	10	has	-
wsj_1934.en	0	11	been	-
wsj_1934.en	0	12	successfully	-
wsj_1934.en	0	13	used	-
wsj_1934.en	0	14	on	-
wsj_1934.en	0	15	more	(1
wsj_1934.en	0	16	than	-
wsj_1934.en	0	17	100	-
wsj_1934.en	0	18	patients	1)
wsj_1934.en	0	19	at	-
wsj_1934.en	0	20	the	(2
wsj_1934.en	0	21	University	-
wsj_1934.en	0	22	of	-
wsj_1934.en	0	23	Pittsburgh	2)
wsj_1934.en	0	24	,	-
wsj_1934.en	0	25	according	-
wsj_1934.en	0	26	to	-
wsj_1934.en	0	27	researchers	-
wsj_1934.en	0	28	.	-

wsj_1934.en	0	0	The	(3
wsj_1934.en	0	1	drug	-
wsj_1934.en	0	2	,	3)
wsj_1934.en	0	3	which	(3)
wsj_1934.en	0	4	is	-
wsj_1934.en	0	5	still	-
wsj_1934.en	0	6	in	-
wsj_1934.en	0	7	the	-
wsj_1934.en	0	8	experimental	-
wsj_1934.en	0	9	phase	-
wsj_1934.en	0	10	,	-
wsj_1934.en	0	11	has	-
wsj_1934.en	0	12	n't	-
wsj_1934.en	0	13	been	-
wsj_1934.en	0	14	approved	-
wsj_1934.en	0	15	yet	-
wsj_1934.en	0	16	by	-
wsj_1934.en	0	17	the	(9
wsj_1934.en	0	18	Food	-
wsj_1934.en	0	19	and	-
wsj_1934.en	0	20	Drug	-
wsj_1934.en	0	21	Admistration	9)
wsj_1934.en	0	22	,	-
wsj_1934.en	0	23	and	-
wsj_1934.en	0	24	its	(3)
wsj_1934.en	0	25	long-term	-
wsj_1934.en	0	26	effects	-
wsj_1934.en	0	27	are	-
wsj_1934.en	0	28	unknown	-
wsj_1934.en	0	29	.	-

wsj_1934.en	0	0	But	-
wsj_1934.en	0	1	researchers	-
wsj_1934.en	0	2	say	-
wsj_1934.en	0	3	the	(3
wsj_1934.en	0	4	drug	3)
wsj_1934.en	0	5	,	-
wsj_1934.en	0	6	called	-
wsj_1934.en	0	7	FK-506	-
wsj_1934.en	0	8	,	-
wsj_1934.en	0	9	could	-
wsj_1934.en	0	10	revolutionize	-
wsj_1934.en	0	11	the	-
wsj_1934.en	0	12	transplantation	-
wsj_1934.en	0	13	field	-
wsj_1934.en	0	14	by	-
wsj_1934.en	0	15	reducing	-
wsj_1934.en	0	16	harmful	-
wsj_1934.en	0	17	side	-
wsj_1934.en	0	18	effects	-
wsj_1934.en	0	19	and	-
wsj_1934.en	0	20	by	-
wsj_1934.en	0	21	lowering	-
wsj_1934.en	0	22	rejection	-
wsj_1934.en	0	23	rates	-
wsj_1934.en	0	24	.	-

wsj_1934.en	0	0	Rejection	-
wsj_1934.en	0	1	has	-
wsj_1934.en	0	2	been	-
wsj_1934.en	0	3	the	-
wsj_1934.en	0	4	major	-
wsj_1934.en	0	5	obstacle	-
wsj_1934.en	0	6	in	-
wsj_1934.en	0	7	the	(19
wsj_1934.en	0	8	approximately	-
wsj_1934.en	0	9	30,000	-
wsj_1934.en	0	10	organ	-
wsj_1934.en	0	11	transplants	19)
wsj_1934.en	0	12	performed	-
wsj_1934.en	0	13	world-wide	-
wsj_1934.en	0	14	each	-
wsj_1934.en	0	15	year	-
wsj_1934.en	0	16	.	-

wsj_1934.en	0	0	Researchers	(20)
wsj_1934.en	0	1	began	-
wsj_1934.en	0	2	using	-
wsj_1934.en	0	3	the	(3
wsj_1934.en	0	4	drug	3)
wsj_1934.en	0	5	in	-
wsj_1934.en	0	6	February	-
wsj_1934.en	0	7	on	-
wsj_1934.en	0	8	patients	(21)
wsj_1934.en	0	9	who	(21)
wsj_1934.en	0	10	had	-
wsj_1934.en	0	11	received	-
wsj_1934.en	0	12	kidney	-
wsj_1934.en	0	13	,	-
wsj_1934.en	0	14	liver	-
wsj_1934.en	0	15	,	-
wsj_1934.en	0	16	heart	-
wsj_1934.en	0	17	and	-
wsj_1934.en	0	18	pancreas	-
wsj_1934.en	0	19	transplants	-
wsj_1934.en	0	20	.	-

wsj_1934.en	0	0	Only	-
wsj_1934.en	0	1	two	-
wsj_1934.en	0	2	of	-
wsj_1934.en	0	3	111	-
wsj_1934.en	0	4	transplants	-
wsj_1934.en	0	5	have	-
wsj_1934.en	0	6	been	-
wsj_1934.en	0	7	rejected	-
wsj_1934.en	0	8	.	-

wsj_1934.en	0	0	The	(3
wsj_1934.en	0	1	drug	3)
wsj_1934.en	0	2	,	-
wsj_1934.en	0	3	discovered	-
wsj_1934.en	0	4	in	-
wsj_1934.en	0	5	1984	-
wsj_1934.en	0	6	,	-
wsj_1934.en	0	7	is	-
wsj_1934.en	0	8	metabolized	-
wsj_1934.en	0	9	from	-
wsj_1934.en	0	10	soil	(22
wsj_1934.en	0	11	fungus	22)
wsj_1934.en	0	12	found	-
wsj_1934.en	0	13	in	-
wsj_1934.en	0	14	Japan	-
wsj_1934.en	0	15	.	-

wsj_1934.en	0	0	The	(1
wsj_1934.en	0	1	Pittsburgh	(2)
wsj_1934.en	0	2	patients	1)
wsj_1934.en	0	3	are	-
wsj_1934.en	0	4	the	(23
wsj_1934.en	0	5	first	-
wsj_1934.en	0	6	humans	23)
wsj_1934.en	0	7	to	-
wsj_1934.en	0	8	be	-
wsj_1934.en	0	9	given	-
wsj_1934.en	0	10	the	(3
wsj_1934.en	0	11	drug	3)
wsj_1934.en	0	12	,	-
wsj_1934.en	0	13	which	(3)
wsj_1934.en	0	14	is	-
wsj_1934.en	0	15	made	-
wsj_1934.en	0	16	by	-
wsj_1934.en	0	17	Fujisawa	(16
wsj_1934.en	0	18	Pharmaceutical	-
wsj_1934.en	0	19	Co	16)
wsj_1934.en	0	20	.	-

wsj_1934.en	0	0	``	-
wsj_1934.en	0	1	We	(5)
wsj_1934.en	0	2	're	-
wsj_1934.en	0	3	shocked	-
wsj_1934.en	0	4	by	-
wsj_1934.en	0	5	it	(3)
wsj_1934.en	0	6	,	-
wsj_1934.en	0	7	because	-
wsj_1934.en	0	8	it	(3)
wsj_1934.en	0	9	's	-
wsj_1934.en	0	10	worked	-
wsj_1934.en	0	11	so	-
wsj_1934.en	0	12	fast	-
wsj_1934.en	0	13	,	-
wsj_1934.en	0	14	''	-
wsj_1934.en	0	15	said	-
wsj_1934.en	0	16	Dr.	(8
wsj_1934.en	0	17	Thomas	-
wsj_1934.en	0	18	E.	-
wsj_1934.en	0	19	Starzl	8)
wsj_1934.en	0	20	,	-
wsj_1934.en	0	21	director	(8
wsj_1934.en	0	22	of	-
wsj_1934.en	0	23	the	(10
wsj_1934.en	0	24	University	-
wsj_1934.en	0	25	of	-
wsj_1934.en	0	26	Pittsburgh	-
wsj_1934.en	0	27	Transplantation	-
wsj_1934.en	0	28	Program	8)|10)
wsj_1934.en	0	29	,	-
wsj_1934.en	0	30	at	-
wsj_1934.en	0	31	a	-
wsj_1934.en	0	32	news	-
wsj_1934.en	0	33	conference	-
wsj_1934.en	0	34	here	-
wsj_1934.en	0	35	yesterday	-
wsj_1934.en	0	36	.	-

wsj_1934.en	0	0	``	-
wsj_1934.en	0	1	We	(5)
wsj_1934.en	0	2	consider	-
wsj_1934.en	0	3	it	(3)
wsj_1934.en	0	4	a	-
wsj_1934.en	0	5	life-saving	-
wsj_1934.en	0	6	drug	-
wsj_1934.en	0	7	,	-
wsj_1934.en	0	8	like	-
wsj_1934.en	0	9	one	-
wsj_1934.en	0	10	for	-
wsj_1934.en	0	11	AIDS	-
wsj_1934.en	0	12	,	-
wsj_1934.en	0	13	''	-
wsj_1934.en	0	14	said	-
wsj_1934.en	0	15	Dr.	(4
wsj_1934.en	0	16	John	-
wsj_1934.en	0	17	Fung	4)
wsj_1934.en	0	18	,	-
wsj_1934.en	0	19	an	(4
wsj_1934.en	0	20	immunologist	-
wsj_1934.en	0	21	at	-
wsj_1934.en	0	22	the	(2
wsj_1934.en	0	23	University	-
wsj_1934.en	0	24	of	-
wsj_1934.en	0	25	Pittsburgh	2)|4)
wsj_1934.en	0	26	.	-

wsj_1934.en	0	0	Researchers	(6)
wsj_1934.en	0	1	say	-
wsj_1934.en	0	2	they	(6)
wsj_1934.en	0	3	believe	-
wsj_1934.en	0	4	FK-506	(3)
wsj_1934.en	0	5	is	-
wsj_1934.en	0	6	100	-
wsj_1934.en	0	7	times	-
wsj_1934.en	0	8	more	-
wsj_1934.en	0	9	effective	-
wsj_1934.en	0	10	than	-
wsj_1934.en	0	11	the	(7|(7
wsj_1934.en	0	12	traditional	-
wsj_1934.en	0	13	anti-rejection	-
wsj_1934.en	0	14	drug	7)
wsj_1934.en	0	15	,	-
wsj_1934.en	0	16	cyclosporine	7)
wsj_1934.en	0	17	,	-
wsj_1934.en	0	18	made	-
wsj_1934.en	0	19	by	-
wsj_1934.en	0	20	Swiss	-
wsj_1934.en	0	21	pharmaceutical	-
wsj_1934.en	0	22	giant	-
wsj_1934.en	0	23	Sandoz	-
wsj_1934.en	0	24	Ltd	-
wsj_1934.en	0	25	.	-

wsj_1934.en	0	0	They	(6)
wsj_1934.en	0	1	are	-
wsj_1934.en	0	2	also	-
wsj_1934.en	0	3	encouraged	-
wsj_1934.en	0	4	by	-
wsj_1934.en	0	5	the	-
wsj_1934.en	0	6	relatively	-
wsj_1934.en	0	7	mild	-
wsj_1934.en	0	8	side	-
wsj_1934.en	0	9	effects	-
wsj_1934.en	0	10	of	-
wsj_1934.en	0	11	FK-506	(3)
wsj_1934.en	0	12	,	-
wsj_1934.en	0	13	compared	(7
wsj_1934.en	0	14	with	-
wsj_1934.en	0	15	cyclosporine	7)
wsj_1934.en	0	16	,	-
wsj_1934.en	0	17	which	(7)
wsj_1934.en	0	18	can	-
wsj_1934.en	0	19	cause	-
wsj_1934.en	0	20	renal	-
wsj_1934.en	0	21	failure	-
wsj_1934.en	0	22	,	-
wsj_1934.en	0	23	morbidity	-
wsj_1934.en	0	24	,	-
wsj_1934.en	0	25	nausea	-
wsj_1934.en	0	26	and	-
wsj_1934.en	0	27	other	-
wsj_1934.en	0	28	problems	-
wsj_1934.en	0	29	.	-

wsj_1934.en	0	0	``	-
wsj_1934.en	0	1	The	-
wsj_1934.en	0	2	side	-
wsj_1934.en	0	3	effects	-
wsj_1934.en	0	4	-LCB-	-
wsj_1934.en	0	5	of	-
wsj_1934.en	0	6	cyclosporine	(7)
wsj_1934.en	0	7	-RCB-	-
wsj_1934.en	0	8	have	-
wsj_1934.en	0	9	made	-
wsj_1934.en	0	10	the	-
wsj_1934.en	0	11	penalty	-
wsj_1934.en	0	12	for	-
wsj_1934.en	0	13	its	(7)
wsj_1934.en	0	14	success	-
wsj_1934.en	0	15	rather	-
wsj_1934.en	0	16	high	-
wsj_1934.en	0	17	,	-
wsj_1934.en	0	18	''	-
wsj_1934.en	0	19	Dr.	(8
wsj_1934.en	0	20	Starzl	8)
wsj_1934.en	0	21	said	-
wsj_1934.en	0	22	.	-

wsj_1934.en	0	0	Dr.	(4
wsj_1934.en	0	1	Fung	4)
wsj_1934.en	0	2	said	-
wsj_1934.en	0	3	that	-
wsj_1934.en	0	4	FK-506	(3)
wsj_1934.en	0	5	would	-
wsj_1934.en	0	6	not	-
wsj_1934.en	0	7	be	-
wsj_1934.en	0	8	available	-
wsj_1934.en	0	9	in	-
wsj_1934.en	0	10	the	-
wsj_1934.en	0	11	market	-
wsj_1934.en	0	12	for	-
wsj_1934.en	0	13	at	-
wsj_1934.en	0	14	least	-
wsj_1934.en	0	15	a	-
wsj_1934.en	0	16	year	-
wsj_1934.en	0	17	,	-
wsj_1934.en	0	18	and	-
wsj_1934.en	0	19	that	-
wsj_1934.en	0	20	the	-
wsj_1934.en	0	21	FDA	(9)
wsj_1934.en	0	22	approval	-
wsj_1934.en	0	23	process	-
wsj_1934.en	0	24	usually	-
wsj_1934.en	0	25	takes	-
wsj_1934.en	0	26	three	-
wsj_1934.en	0	27	years	-
wsj_1934.en	0	28	to	-
wsj_1934.en	0	29	five	-
wsj_1934.en	0	30	years	-
wsj_1934.en	0	31	.	-

wsj_1934.en	0	0	There	-
wsj_1934.en	0	1	are	-
wsj_1934.en	0	2	no	-
wsj_1934.en	0	3	firm	-
wsj_1934.en	0	4	plans	-
wsj_1934.en	0	5	to	-
wsj_1934.en	0	6	expand	-
wsj_1934.en	0	7	the	(10
wsj_1934.en	0	8	experimental	-
wsj_1934.en	0	9	program	10)
wsj_1934.en	0	10	beyond	-
wsj_1934.en	0	11	the	(2
wsj_1934.en	0	12	University	-
wsj_1934.en	0	13	of	-
wsj_1934.en	0	14	Pittsburgh	2)
wsj_1934.en	0	15	,	-
wsj_1934.en	0	16	whose	(2)|(11
wsj_1934.en	0	17	hospital	11)
wsj_1934.en	0	18	performs	-
wsj_1934.en	0	19	the	-
wsj_1934.en	0	20	most	-
wsj_1934.en	0	21	transplants	-
wsj_1934.en	0	22	in	-
wsj_1934.en	0	23	the	-
wsj_1934.en	0	24	world	-
wsj_1934.en	0	25	.	-

wsj_1934.en	0	0	Researchers	(13)
wsj_1934.en	0	1	could	-
wsj_1934.en	0	2	n't	-
wsj_1934.en	0	3	estimate	-
wsj_1934.en	0	4	the	-
wsj_1934.en	0	5	cost	-
wsj_1934.en	0	6	of	-
wsj_1934.en	0	7	the	(3
wsj_1934.en	0	8	drug	3)
wsj_1934.en	0	9	when	-
wsj_1934.en	0	10	it	(3)
wsj_1934.en	0	11	reaches	-
wsj_1934.en	0	12	the	-
wsj_1934.en	0	13	market	-
wsj_1934.en	0	14	,	-
wsj_1934.en	0	15	but	-
wsj_1934.en	0	16	they	(13)
wsj_1934.en	0	17	said	-
wsj_1934.en	0	18	FK-506	(3)
wsj_1934.en	0	19	will	-
wsj_1934.en	0	20	enable	-
wsj_1934.en	0	21	patients	(14)
wsj_1934.en	0	22	to	-
wsj_1934.en	0	23	cut	-
wsj_1934.en	0	24	hospital	-
wsj_1934.en	0	25	stays	-
wsj_1934.en	0	26	by	-
wsj_1934.en	0	27	50	-
wsj_1934.en	0	28	%	-
wsj_1934.en	0	29	and	-
wsj_1934.en	0	30	reduce	-
wsj_1934.en	0	31	the	-
wsj_1934.en	0	32	number	-
wsj_1934.en	0	33	of	-
wsj_1934.en	0	34	blood	(15
wsj_1934.en	0	35	tests	15)
wsj_1934.en	0	36	used	-
wsj_1934.en	0	37	to	-
wsj_1934.en	0	38	monitor	-
wsj_1934.en	0	39	the	-
wsj_1934.en	0	40	dosage	-
wsj_1934.en	0	41	of	-
wsj_1934.en	0	42	cyclosporine	(7)
wsj_1934.en	0	43	and	-
wsj_1934.en	0	44	other	(3
wsj_1934.en	0	45	drugs	3)
wsj_1934.en	0	46	among	-
wsj_1934.en	0	47	transplant	-
wsj_1934.en	0	48	recipients	-
wsj_1934.en	0	49	.	-

wsj_1934.en	0	0	Dr.	(8
wsj_1934.en	0	1	Starzl	8)
wsj_1934.en	0	2	said	-
wsj_1934.en	0	3	the	(17
wsj_1934.en	0	4	research	17)
wsj_1934.en	0	5	has	-
wsj_1934.en	0	6	been	-
wsj_1934.en	0	7	largely	-
wsj_1934.en	0	8	financed	-
wsj_1934.en	0	9	by	-
wsj_1934.en	0	10	the	-
wsj_1934.en	0	11	National	-
wsj_1934.en	0	12	Institute	-
wsj_1934.en	0	13	of	-
wsj_1934.en	0	14	Health	-
wsj_1934.en	0	15	and	-
wsj_1934.en	0	16	by	-
wsj_1934.en	0	17	university	(2)
wsj_1934.en	0	18	funds	-
wsj_1934.en	0	19	,	-
wsj_1934.en	0	20	and	-
wsj_1934.en	0	21	that	-
wsj_1934.en	0	22	Fujisawa	(16)
wsj_1934.en	0	23	did	-
wsj_1934.en	0	24	n't	-
wsj_1934.en	0	25	give	-
wsj_1934.en	0	26	the	(11
wsj_1934.en	0	27	hospital	11)
wsj_1934.en	0	28	any	-
wsj_1934.en	0	29	grants	-
wsj_1934.en	0	30	.	-

wsj_1934.en	0	0	He	(8)
wsj_1934.en	0	1	said	-
wsj_1934.en	0	2	that	-
wsj_1934.en	0	3	the	(13
wsj_1934.en	0	4	research	(17)
wsj_1934.en	0	5	team	13)
wsj_1934.en	0	6	had	-
wsj_1934.en	0	7	no	-
wsj_1934.en	0	8	financial	-
wsj_1934.en	0	9	stake	-
wsj_1934.en	0	10	in	-
wsj_1934.en	0	11	the	(3
wsj_1934.en	0	12	drug	3)
wsj_1934.en	0	13	.	-

wsj_1934.en	0	0	``	-
wsj_1934.en	0	1	We	(13)
wsj_1934.en	0	2	've	-
wsj_1934.en	0	3	known	-
wsj_1934.en	0	4	for	-
wsj_1934.en	0	5	six	-
wsj_1934.en	0	6	months	-
wsj_1934.en	0	7	the	-
wsj_1934.en	0	8	effect	-
wsj_1934.en	0	9	of	-
wsj_1934.en	0	10	this	(3
wsj_1934.en	0	11	drug	3)
wsj_1934.en	0	12	,	-
wsj_1934.en	0	13	and	-
wsj_1934.en	0	14	our	(13)
wsj_1934.en	0	15	advice	-
wsj_1934.en	0	16	to	(18
wsj_1934.en	0	17	our	(13)
wsj_1934.en	0	18	people	18)
wsj_1934.en	0	19	has	-
wsj_1934.en	0	20	been	-
wsj_1934.en	0	21	not	-
wsj_1934.en	0	22	to	-
wsj_1934.en	0	23	buy	-
wsj_1934.en	0	24	the	(16
wsj_1934.en	0	25	company	-
wsj_1934.en	0	26	's	16)
wsj_1934.en	0	27	stock	-
wsj_1934.en	0	28	,	-
wsj_1934.en	0	29	''	-
wsj_1934.en	0	30	Dr.	(8
wsj_1934.en	0	31	Starzl	8)
wsj_1934.en	0	32	said	-
wsj_1934.en	0	33	,	-
wsj_1934.en	0	34	adding	-
wsj_1934.en	0	35	that	-
wsj_1934.en	0	36	profiting	-
wsj_1934.en	0	37	from	-
wsj_1934.en	0	38	FK-506	(3)
wsj_1934.en	0	39	would	-
wsj_1934.en	0	40	n't	-
wsj_1934.en	0	41	be	-
wsj_1934.en	0	42	ethical	-
wsj_1934.en	0	43	.	-

#end document 